Trial · NCT00360282

Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?

NCT00360282, Not applicable, Completed, University of Pittsburgh; results first posted 2014-12-08

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines? Trials, record NCT00360282. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00360282

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?
NCT number: NCT00360282
Status: Completed
Phases: Not applicable
Enrollment: 36 participants, actual
Lead sponsor: University of Pittsburgh
Conditions: Migraine
Interventions: Rizatriptan, Placebo
First posted: 2006-08-04
Last updated: 2014-12-08
Results first posted: 2014-12-08

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change From Baseline in Motion Sickness to Post Vestibular Stimulus	Pre and Post Stimulus (about 6 minutes apart)	Scores are based on a scale developed by Graybiel which rates seven subjective and objective signs of motion sickness. The total scores ranged from from 0 to 25. Zero indicating no motion sickness. Greater than 16 indicates severe motion sickness. Trials were stopped if scores were 16 or greater. Scores were taken before and after each rotation.
Secondary	Change From Baseline in Subjective Units of Distress to Post Vestibular Stimulus	Pre and Post Stimulus (6 minutes apart)	Subjective report of distress ranging from 0 to 10 based on the method of Wolpe. Zero indicates no distress and 10 indicates severe distress. Measures used in this analysis match the times used in the analysis for Outcome 1.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change From Baseline in Motion Sickness to Post Vestibular Stimulus	Pre and Post Stimulus (about 6 minutes apart)	Ten of the 25 subjects who completed both experimental visits developed negligible motion sickness induced by the stimulus following pre-medication with placebo. These data were not analyzed. It was posited that the presence/absence of vertigo would not impact the analysis of this outcome. The groups were combined for the analysis.	units on a scale	MEDIAN
SECONDARY	Change From Baseline in Subjective Units of Distress to Post Vestibular Stimulus	Pre and Post Stimulus (6 minutes apart)	Ten of the 25 subjects who completed both experimental visits developed negligible motion sickness induced by the stimulus following pre-medication with placebo. These data were not analyzed. It was posited that the presence/absence of vertigo would not impact the analysis of this outcome. The groups were combined for the analysis.	units on a scale	MEDIAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change From Baseline in Motion Sickness to Post Vestibular Stimulus	Rizatriptan Visit	5.1	Inter-Quartile Range 2 to 10	units on a scale
Change From Baseline in Motion Sickness to Post Vestibular Stimulus	Placebo Visit	9	Inter-Quartile Range 4.9 to 10.9	units on a scale
Change From Baseline in Subjective Units of Distress to Post Vestibular Stimulus	Rizatriptan Visit	3	Inter-Quartile Range 0 to 5	units on a scale
Change From Baseline in Subjective Units of Distress to Post Vestibular Stimulus	Placebo Visit	2	Inter-Quartile Range 1 to 4	units on a scale

Source ClinicalTrials.gov

Participant flow36

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
First Intervention	STARTED	With Vertigo; Placebo-Rizatriptan	6
First Intervention	STARTED	Without Vertigo; Placebo - Rizatriptan	8
First Intervention	STARTED	With Vertigo; Rizatriptan - Placebo	7
First Intervention	STARTED	Without Vertigo; Rizatriptan - Placebo	6
First Intervention	COMPLETED	With Vertigo; Placebo-Rizatriptan	6
First Intervention	COMPLETED	Without Vertigo; Placebo - Rizatriptan	8
First Intervention	COMPLETED	With Vertigo; Rizatriptan - Placebo	7
First Intervention	COMPLETED	Without Vertigo; Rizatriptan - Placebo	6
First Intervention	NOT COMPLETED	With Vertigo; Placebo-Rizatriptan	0
First Intervention	NOT COMPLETED	Without Vertigo; Placebo - Rizatriptan	0

1 to 10 of 36Source ClinicalTrials.gov

See all 36 participant flow

Adverse events8

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Increased Blood Pressure	General disorders	Without Vertigo; Placebo	1	14	1
other	Increased Blood Pressure	General disorders	Without Vertigo; Rizatriptan	0	14	0
other	Increased Blood Pressure	General disorders	With Vertigo; Placebo	0	12	0
other	Increased Blood Pressure	General disorders	With Vertigo; Rizatriptan	0	13	0
other	Nausea	General disorders	Without Vertigo; Placebo	1	14	1
other	Nausea	General disorders	Without Vertigo; Rizatriptan	0	14	0
other	Nausea	General disorders	With Vertigo; Placebo	0	12	0
other	Nausea	General disorders	With Vertigo; Rizatriptan	0	13	0

Source ClinicalTrials.gov

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Without Vertigo; Placebo
Total, all-cause mortality	Without Vertigo; Rizatriptan
Total, all-cause mortality	With Vertigo; Placebo
Total, all-cause mortality	With Vertigo; Rizatriptan
Total, other adverse events	Without Vertigo; Placebo	1	14
Total, other adverse events	Without Vertigo; Rizatriptan	0	14
Total, other adverse events	With Vertigo; Placebo	0	12
Total, other adverse events	With Vertigo; Rizatriptan	0	13
Total, serious adverse events	Without Vertigo; Placebo	0	14
Total, serious adverse events	Without Vertigo; Rizatriptan	0	14

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
20862509	RESULT	PubMed
37042545	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00360282

GET https://conductscience.org/api/trials/v1/NCT00360282/flow?page=2

API reference For AI assistants